| Literature DB >> 22929879 |
J A van der Zee1, C H J van Eijck, W C J Hop, K Biermann, B M Dicheva, A Lb Seynhaeve, G A Koning, A M M Eggermont, T L M Ten Hagen.
Abstract
BACKGROUND: Although widely fragmented BMs have been associated with adverse outcome in several cancer types, comparatively little is known with respect to its effect on the prognosis of pancreatic cancer. The aim of the current study was therefore to determine the prognostic value of tumour basement membrane (BM) continuity in two anatomically closely related, however, prognostically different tumours, pancreatic head- and periampullary cancer.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22929879 PMCID: PMC3461165 DOI: 10.1038/bjc.2012.373
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Pancreatic cancer staining with anti-laminin showing both basement membrane and tumour cell staining. (A) × 10 magnification. (B) × 20 magnification.
Figure 2Pancreatic cancer staining with anti-collagen type IV showing both basement membrane staining and staining of tumour stroma. (A) × 10 magnification. (B) × 20 magnification.
Figure 3Recurrence-free survival (RFS) of patients treated for, respectively, pancreatic head (A) and periampullary cancer (B) shows shorter RFS in patients with tumours with limited basement membrane (BM) laminin expression compared to those with tumours with more continuous BM laminin expression. This different survival behaviour, however, was only significant for pancreatic head cancers (P=0.034 and 0.16 for pancreatic head and periampullary cancer, respectively).
5-Year survival and multivariate analysis of conventional prognostic factors and tumour BM laminin expression on outcome following curative resection of pancreatic head cancer
|
|
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Tumour extension | 0.30 | 0.18 | 0.39 | ||||||||||
| T1/2 | 14 | 29 | 31 | 29 | |||||||||
| T3/4 | 76 | 13 | 1.41 | 0.74–2.69 | 17 | 1.67 | 0.78–3.56 | 14 | 1.33 | 0.69–2.55 | |||
| Nodal involvement | 0.024 | 0.006 | 0.006 | ||||||||||
| No | 43 | 30 | 35 | 32 | |||||||||
| Yes | 49 | 3 | 1.75 | 1.08–2.86 | 3 | 2.10 | 1.24–3.54 | 2 | 1.98 | 1.22–3.22 | |||
| Differentiation | 0.09 | 0.08 | 0.10 | ||||||||||
| Well | 15 | 33 | 38 | 33 | |||||||||
| Moderately | 60 | 12 | 1.99 | 1.04–3.80 | 0.037 | 15 | 1.84 | 0.89–3.83 | 0.10 | 13 | 1.97 | 1.03–3.76 | 0.040 |
| Poorly | 16 | 13 | 2.12 | 0.98–4.59 | 0.056 | 13 | 2.69 | 1.14–6.36 | 0.024 | 13 | 2.02 | 0.93–4.41 | 0.08 |
| BM Laminin expression | 0.09 | 0.043 | 0.050 | ||||||||||
| Limited | 55 | 10 | 11 | 10 | |||||||||
| ⩾25% | 37 | 26 | 0.67 | 0.42–1.07 | 31 | 0.59 | 0.35–0.98 | 27 | 0.63 | 0.39–1.00 | |||
Abbreviations: BM=basement membrane; 95% CI=95% confidence interval; CSS=cancer-specific survival; HR=hazard ratio; OS=overall survival; RFS=recurrence-free survival; % 5 year=% 5 year survival by univariate analysis.
Reference category.